ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    park2 and sack
Previous Study | Return to List | Next Study

Mutations Associated With Parkinson s Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01547832
Recruitment Status : Terminated
First Posted : March 8, 2012
Last Update Posted : August 29, 2018
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Heart, Lung, and Blood Institute (NHLBI) )

Brief Summary:

Background:

- Early-onset Parkinson's disease (EOPD) is more likely to be caused by gene mutations than Parkinson's disease that develops in older people. Studying these mutations may help find therapies for EOPD. Researchers want to study mutations on a gene called PARK2. These mutations prevent fat uptake into cells and may interfere with normal brain function. Researchers want to study fat and cholesterol in the body to look at the effects of these mutations on the body and brain.

Objectives:

- To study connections between genetic mutations and EOPD.

Eligibility:

  • Individuals between 18 and 80 years of age with EOPD.
  • Individuals between 18 and 80 years of age with no family history of Parkinson s disease.

Design:

  • Participants will be screened with a physical exam and medical history. Blood and urine samples will also be collected.
  • Participants will have some or all of the following tests:
  • Blood samples and tissue (skin and fat) biopsies
  • Cell line development from these tissue samples to study the function of PARK2
  • DEXA scan to measure body fat context using low dose x-rays
  • Glucose and insulin tolerance testing to measure blood sugar levels.
  • Treatment will not be provided as part of this protocol.

Condition or disease
Parkinson's Disease

Detailed Description:
The majority of subjects with the degenerative Parkinson s Disease present at around the age of 70 years. Other subjects develop this brain disease before the age of 40 years. This early onset presentation is more likely to have a direct genetic cause than the degenerative form of the disease. Our understanding of the genetic causes of early onset Parkinson s Disease may help us find therapies for both the genetic and more degenerative illnesses. Our laboratory has found that one of the genetic mutations associated with early onset Parkinson s Disease, in a gene called PARK2 results in impaired uptake of fat into cells. This may have detrimental effects in the brain, as the brain requires fat to make cholesterol and to send brain signals. A finding in mice lacking PARK2, is that they are resistant to diet induced diabetes and obesity and to fatty liver. These data suggests that the systemic and brain effects of low fat uptake may be opposing, with low fat uptake having a beneficial effect against risk factors such as obesity and diabetes but increasing the risk for brain diseases. To begin to test whether this is the case in subjects with PARK2 mutations we propose to test their fat uptake and glucose and insulin sensitivity.

Study Type : Observational
Actual Enrollment : 42 participants
Time Perspective: Prospective
Official Title: Metabolic Phenotyping of Subjects With Mutations Associated With Hereditary Parkinson's Disease
Study Start Date : February 27, 2012
Study Completion Date : August 27, 2018






Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria
  • INCLUSION CRITERIA:

Parkinson s Subjects:

Screening:

  • Age 18 years to 80 years old with a history of early onset Parkinson disease (Presentation within the first five decades of life).
  • Diagnosis of Parkinson disease or Parkinsonism
  • Willingness and legal ability to give and sign informed study consent

Enrollment:

  • Mutations in PARK2
  • Willingness to travel to NIH for scheduled protocol studies

Control Subjects:

  • Age 18 years to 80 years old with no history or family history of Parkinson disease.
  • Willingness and legal ability to give and sign informed study consent
  • Willingness to travel to NIH for scheduled protocol studies
  • Willingness to have blood or tissue samples studied, and potentially stored for future research

EXCLUSION CRITERIA: <TAB>

Parkinson Subjects:

Screening:

  • Subjects who are unable or unwilling to sign an informed consent subjects with genetic defects associated with other diseases including other neurologic syndromes.
  • Subjects without medically treated diabetes who are unable/unwilling to undergo a glucose tolerance test

Enrollment:

- Pregnancy

Control Subjects

  • Subjects who are unable or unwilling to sign an informed consent
  • Subjects with genetic defects associated with other diseases including other neurologic syndromes.
  • Pregnancy
  • Medically treated diabetes
  • Unable/unwilling to undergo a glucose tolerance test

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01547832


Locations
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Investigators
Principal Investigator: Michael N Sack, M.D. National Heart, Lung, and Blood Institute (NHLBI)

Publications:
Responsible Party: National Heart, Lung, and Blood Institute (NHLBI)
ClinicalTrials.gov Identifier: NCT01547832     History of Changes
Other Study ID Numbers: 120084
12-H-0084
First Posted: March 8, 2012    Key Record Dates
Last Update Posted: August 29, 2018
Last Verified: August 27, 2018

Keywords provided by National Institutes of Health Clinical Center (CC) ( National Heart, Lung, and Blood Institute (NHLBI) ):
Cholesterol
Early Onset Parkinson's Disease
Fat Metabolism
Insulin Resistance
PARK2 Mutations

Additional relevant MeSH terms:
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases